Anti-CYP2D6 monoclonal antibody
Pre-made anti-CYP2D6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CYP2D6/CYP2D6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0015-Ab-1/ GM-Tg-hg-IP0015-Ab-2 | Anti-Human CYP2D6 monoclonal antibody | Human |
GM-Tg-rg-IP0015-Ab-1/ GM-Tg-rg-IP0015-Ab-2 | Anti-Rat CYP2D6 monoclonal antibody | Rat |
GM-Tg-mg-IP0015-Ab-1/ GM-Tg-mg-IP0015-Ab-2 | Anti-Mouse CYP2D6 monoclonal antibody | Mouse |
GM-Tg-cynog-IP0015-Ab-1/ GM-Tg-cynog-IP0015-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP2D6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0015-Ab-1/ GM-Tg-felg-IP0015-Ab-2 | Anti-Feline CYP2D6 monoclonal antibody | Feline |
GM-Tg-cang-IP0015-Ab-1/ GM-Tg-cang-IP0015-Ab-2 | Anti-Canine CYP2D6 monoclonal antibody | Canine |
GM-Tg-bovg-IP0015-Ab-1/ GM-Tg-bovg-IP0015-Ab-2 | Anti-Bovine CYP2D6 monoclonal antibody | Bovine |
GM-Tg-equg-IP0015-Ab-1/ GM-Tg-equg-IP0015-Ab-2 | Anti-Equine CYP2D6 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0015-Ab-1/ GM-Tg-hg-IP0015-Ab-2; GM-Tg-rg-IP0015-Ab-1/ GM-Tg-rg-IP0015-Ab-2; GM-Tg-mg-IP0015-Ab-1/ GM-Tg-mg-IP0015-Ab-2; GM-Tg-cynog-IP0015-Ab-1/ GM-Tg-cynog-IP0015-Ab-2; GM-Tg-felg-IP0015-Ab-1/ GM-Tg-felg-IP0015-Ab-2; GM-Tg-cang-IP0015-Ab-1/ GM-Tg-cang-IP0015-Ab-2; GM-Tg-bovg-IP0015-Ab-1/ GM-Tg-bovg-IP0015-Ab-2; GM-Tg-equg-IP0015-Ab-1/ GM-Tg-equg-IP0015-Ab-2 |
Products Name | Anti-CYP2D6 monoclonal antibody |
Format | mab |
Target Name | CYP2D6 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CYP2D6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0015-Ag-1 | Recombinant multi-species CP2D6/ CYP2D6/ CPD6 protein |
ORF Viral Vector | vGMLP002840 | human CYP2D6 Lentivirus particle |
ORF Viral Vector | pGMLP002840 | human CYP2D6 Lentivirus plasmid |
Target information
Target ID | GM-IP0015 |
Target Name | CYP2D6 |
Gene ID | 1565,415120,100500743 |
Gene Symbol and Synonyms | CPD6,CYP2D,CYP2D15,CYP2D6,CYP2D7AP,CYP2D7BP,CYP2D7P2,CYP2D8P2,CYP2DL1,CYPIID15,CYPIID6,P450-DB1,P450C2D,P450DB1 |
Uniprot Accession | P10635,Q29473 |
Uniprot Entry Name | CP2D6_HUMAN,CP2DF_CANLF |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000100197 |
Target Classification | Tumor-associated antigen (TAA) |
The target: CYP2D6, gene name: CYP2D6, also named as CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary in copy number and individuals with the ultrarapid metabolizer phenotype can have 3 or more active copies of the gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.